Sequella Home Page

Quick Facts

There are 425,000 MDR-TB cases a year worldwide, mostly in China, India, and former Soviet Union

Board of Directors

Carol A. Nacy, Ph.D.

Co-Founder, Chief Executive Officer, Chairman of the Board of Directors
Dr. Nacy co-founded our company in 1997 and has served as our CEO and Chairman of the Board since 1999. Prior to devoting herself full-time to Sequella, Dr. Nacy served during 1997 and 1998 as part-time Chief Scientific Officer (CSO) for Anergen, Inc., a California company focused on autoimmune diseases, where she reorganized the scientific staff and positioned the company for acquisition by Corixa Corporation in December 1998. From 1993 through 1997, Dr. Nacy was Executive Vice President and CSO at EntreMed, Inc., serving that company through its successful public offering in June 1996. Previously, Dr. Nacy was Career Scientist (GS-15) and Science Manager at the Walter Reed Army Institute of Research, Washington, DC. In addition to her service to Sequella, Dr. Nacy currently serves as a member of the board of directors of several companies and non-profit agencies. She maintains strong ties to the scientific research community, serving as President of the 43,000 member American Society for Microbiology in 1996 and on the Board of the National Academy of Science, National Research Council from 1996-2003.

Leo Einck, Ph.D.

Co-Founder, Director, and Chief Scientific Officer
Dr. Einck, a co-founder of our company, joined Sequella as President in 1998. He has been involved in the pharmaceutical industry since 1985, and has started and managed several biotechnology companies since his shift to product development. He was the first employee of and later became the Chief Operating Officer of HEM (now Hemispherix), a public company specializing in double-stranded RNA therapeutics for cancer. He managed all aspects of HEM's business, from manufacturing, clinical trials, regulatory affairs, to daily operations. He joined EntreMed, Inc. in 1993 as Director of Sponsored Research, became Vice-President for Extramural Programs in 1996, and then the Vice President for Research Operations. Prior to his business experience, Dr. Einck was a molecular biologist at the National Cancer Institute of the NIH.

Bradley Rotter

Mr. Rotter has been a public and private venture investor in telecommunications, aeronautics, and biotechnology for 25 years and has experience as Chairman of a publicly traded Venture Firm. He currently serves on the Board of AirPatrol Corporation. He was President and then CEO of MR3 Systems, Inc, a Metals Technology Company, one of Mr. Rotter’s portfolio companies, in San Francisco based company is a publicly traded company that has developed a revolutionary technology for the extraction of metals. He is a graduate of West Point and is active in local politics in California.

John H. Friedman, J.D.

John H. Friedman is the Founding and Managing Partner of Easton Capital Investment Group. Prior to founding Easton Capital, John was the founder and Managing General Partner of Security Pacific Capital Investors. Security Pacific Capital Investors was a $200-million private equity fund geared towards expansion financings and recapitalizations. Prior to joining Security Pacific, John was a Managing Director and Partner at E.M. Warburg, Pincus & Co., Inc., where he spent eight and a half years. Previously, John was an attorney with Sullivan and Cromwell. He holds a JD degree from Yale Law School and a BA degree, magna cum laude and Phi Beta Kappa, from Yale College. Mr. Friedman currently serves on the Boards of Promedior, Experimed, Trellis Bioscience, Cardiovascular Systems, iTherX, and PlaySpan. He was also co-chairman of the President's Council at the Cold Spring Harbor Laboratory and serves as a Trustee of The New Museum of Contemporary Art.

Ronald Meltzer, Ph.D., J.D.

Dr. Meltzer has served on our Board of Directors since 1999. Dr. Meltzer was a Distinguished Professor of Political Science specializing in north-south (developed nation to underdeveloped nation) product trade at the State University of New York, Buffalo, for 15 years prior to attending law school. He completed law school with distinction and is currently at the law firm of Wilmer, Cutler & Pickering in Washington, DC.

Kenneth R. Lynn, J.D., MBA

Mr. Lynn was EVP Business Development for NewLink Genetics Corp, a public oncology-focused immunotherapeutics company, from 2008 until 2012. He works with a variety of non-profit public and private institutions that support entrepreneurship and medical innovation, including the Ewing Marion Kauffman Foundation. His prior corporate experience in public and private healthcare companies includes positions in Corporate Development and Legal Affairs (RxKinetics, Valentis), General Counsel (U.S. Biosciences), Corporate Counsel (Marion Merrill Dow), and President and CEO (Cortech).

Paige MacDonald, CPA

Ms. MacDonald is currently CEO of The Highland Group, a real estate development corporation in Montana. She has a variety of experiences in both for-profit and non-profit organizations. From 2002-2005, she was acting CEO and COO of Aeras Global TB Vaccine Foundation, a non-profit funded by the Bill and Melinda Gates Foundation; from 1998-2002 she expanded the retail furniture store, French Country Living, and developed a highly successful retail catalog marketing strategy; from 1975 to 1997 she was COO of the World Wildlife Fund (U.S.) and World Wildlife Foundation. She started her career as a CPA for Price Waterhouse Coopers.

Lawrence Miller

Mr. Miller serves as secretary of the Board of Directors of the Company, but is a nonvoting member. He is also the Corporate Attorney for the Company and has been instrumental in its organization and development of its structure. Mr. Miller has been a Partner in the law firm Grossberg, Yochelson, Fox, & Beyda, in Washington D.C., for thirty years. A significant portion of his practice has been devoted to corporate law as it relates to healthcare organizations.

William Hoskins

Director Emeritus
Mr. Hoskins has a wealth of experience in corporate partnering of new technologies with pharmaceutical companies. Mr. Hoskins was Vice President, Secretary, and General Counsel for the North American operations of Marion, Marion Merrill Dow, and Hoeschst Marion Roussel (now Aventis), where he helped create corporate partnerships of his organizations with a variety of small and large pharmaceutical companies and organized the acquisition of equity interests in a number of companies. He is and has been on the Board of a number of companies and is a Director of the American Arbitration Association. Mr. Hopkins is currently a partner in Resolution Counsel, LLP, a very successful Boston, MA, organization he co-founded to assist in the resolution of disputes between corporate entities.